Resolute Bio (re-launched from OmicVision Biosciences) has engineered its Deep Visual Proteomics-based technology into ResOne, a high-throughput, AI-native data generation platform. ResOne studies proteins in their native human tissue context, which the company says opens a new dimension of biological understanding. The co-founders include Dr. Andreas Mund—credited with pioneering Deep Visual Proteomics—and Maximilian Strauss, with Ishani Ummat serving as CEO. The company states its technology has had direct impact on patient care and frames Resolute as a molecular intelligence company focused on discovering protein context rather than designing molecules. Resolute announced a €10 million seed raise to support the platform and company launch. The firm traces its story back to late 2023 when its work began.

Total raised

$12M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2026